Get Updates

Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Research & Clinical Trials > Study Search Tool > A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

| More

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

This study is open to:

BRCA mutation-positive advanced pancreatic, prostate, ovarian or triple-negative breast cancer:

  • pancreatic cancer for which patient received up to 1 prior line of chemotherapy.
  • castration-resistant prostate cancer (CRPC) for which the patient received up to 2 prior lines of chemotherapy for advanced disease.
  • ovarian cancer or triple-neagtive breast cancer for which the patient received up to 3 prior lines of chemotherapy for advanced disease.

Any advanced solid tumors in people with one of the following mutations: BRCA, ATM, CHEK2, PALB2, RAD51D, or abnormal HRD test (homologous repair deficiency). These patients must have received up to 3 prior lines of chemotherapy in the advanced disease setting.

This study is not open to:

Participating patients must not have:

  • History of leptomeningeal disease or spinal cord compression
  • Underwent major surgery within 4 weeks before first treatment. Received cancer-directed therapy 14 days (6 weeks for mitomycin C and nitrosoureas) before start of treatment
  • Grade 2 or greater peripheral neuropathy at start of treatment
  • Pregnant or nursing women
  • Primary brain tumor
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

A Study on the Safety of BTP-114 for Treatment in Patients with Advanced Solid Tumors with BRCA Mutations

Clinicaltrials.gov identifier:
NCT02950064

Treatment:
Breast
Ovarian
Pancreatic
Prostate

Study Contact Information

Principal Investigator: Erika P Hamilton, MD Tennessee Oncology, PLLC

Click to email 

Study sites: (People interested in the study should contact the email address above). 

  • Sarasota, FL; Boston, MA; Saint Louis, MO; Cleveland, OH; Oklahoma City, OK; Nashville, TN. 

About the Study

This is an early-phase (phase 1) study on a new type of platinum chemotherapy called BTP-114, for patients with advanced cancer caused by a BRCA mutation or other mutation in genes associated with repairing DNA damage. The study is open to patients with breast, ovarian, pancreatic, prostate and other solid tumor cancers. 

Type of Study

The study is "open label" which means that all patients in the study will receive the new agent.

Study Goal

The goal is to stuy the safety and effectiveness of the drug for treating people with advanced cancers. 

What Does Participation Entail?

Participants will receive IV treatment of BTP-114 in 21-day cycles. There will be two parts to this study.

  • Part 1 is a dose-escalation study to detemine the recommended dose for the second part of the study. 
  • Patients recruited into part 2 will receive the "recommended phase 2 dose" as determined by part 1. 

Study Lead Investigator

Principal Investigator: Erika P Hamilton, MD Tennessee Oncology, PLLC

FORCE:Facing Our Risk of Cancer Empowered